225. Congenital nephrogenic diabetes insipidus Disease details / Clinical trials / Drug dev / DR info

Clinical trials : 15 /  Drugs : 48 - (DrugBank : 18) / Drug target genes : 31 - Drug target pathways : 65

Congenital nephrogenic diabetes insipidus and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability
IDDiseases (Sorted by drug repositionability)
225Congenital nephrogenic diabetes insipidus
86Pulmonary arterial hypertension
13Multiple sclerosis/Neuromyelitis optica
115Hereditary periodic paralysis
154Epilepsy with continuous spikes and waves during slow sleep
114Non-dystrophic myotonia syndrome
230Alveolar hypoventilation syndrome
155Acquired aphasia with convulsive disorder
299Cystic fibrosis
90Retinitis pigmentosa
6Parkinson disease
97Ulcerative colitis
67Polycystic kidney disease
51Scleroderma
113Muscular dystrophy
58Hypertrophic cardiomyopathy
46Malignant rheumatoid arthritis
337Homocystinuria
282Congenital dyserythropoietic anemia
77Growth hormone secreting pituitary adenoma
294Congenital diaphragmatic hernia
222Primary nephrotic syndrome
75Cushing disease
88Chronic thromboembolic pulmonary hypertension
65Primary immunodeficiency
210Single Ventricle
49Systemic lupus erythematosus
158Tuberous sclerosis
96Crohn disease
2Amyotrophic lateral sclerosis
271Ankylosing spondylitis
21Mitochondrial disease
298Hereditary pancreatitis
206Fragile X syndrome
301Macular dystrophy
84Sarcoidosis
251Urea cycle disorder
72Pituitary ADH secretion disorder
71Idiopathic osteonecrosis of the femoral head
265Lipodystrophy